Enko improves the Enkompass platform by activating X-Chem’s DNA-encoded library technology

Large datasets will train machine learning models and accelerate the flexible discovery of new crop protection solutions

MYSTIC, Connecticut, June 14, 2022 / PRNewswire / – EnkoCrop Health Company Announces Acquisition of Own DNA-Coded Libraries and Technology Capabilities by Leading Drug Discovery Company X-Chem. Enko was the first company to internalize this technology for agricultural applications. Libraries will help speed up the discovery and development of safe, sustainable crop protection solutions that farmers urgently need.

DNA-encoded libraries are a proven tool for launching pharmaceutical drug discovery projects due to the effectiveness of screening large, diverse chemical spaces. Enko is a pioneer in applying this approach to tackling the challenges of agriculture. This acquisition is a significant advance for Enko’s ENKOMPASS â„¢ platform, which combines DNA-encoded library screening with machine learning and structure-based design to find new chemistry and new ways to control pests and crop diseases. Enko’s targeted discovery method reveals promising chemical starting points for months compared to the years required for traditional research and development approaches.

“Diversity is the foundation and key building block of innovation in the drug design space, and our farmers need it more than ever,” said Enko CEO and Founder Jacqueline Hurd. “Owning these libraries from X-Chem gives us more flexibility to explore the chemical universe and predict which molecule would be appropriate for a particular crop threat. For example, we can fine-tune our screens to focus on a new structure that targets pest enzymes. without harming the bees. It’s similar to the way researchers have adapted cancer drugs to kill cancer cells without affecting others. “

Pairing a DNA-encoded library with machine learning allows Enko to integrate into new chemical spaces, which is crucial to overcoming widespread pest resistance. With these new libraries, each experiment will produce high-quality molecular starting points and training data for machine learning models that increase the efficiency of hit generation and optimization of potential customers. To find safe and effective new ways to deal with pests, Enko can both screen billions of molecules in its DNA-encoded libraries and use artificial intelligence and machine learning to create more effective ways to find and select the right ones. treatments for the right purposes, faster than anyone ever imagined possible.

“The universe of chemicals that can be harvested for safe, effective crop health products is huge. So far, researchers have barely scratched its surface,” he said. Nur Shaker, senior vice president of X-Chem and board member of Enko. “We are champions in the discovery of DEL-based medicines, and our work with Enko has shown the widespread use of this technology to drive more targeted product pipelines in both pharmaceuticals and agriculture.

This technological acquisition follows a year in which Enco has partnered with three of the world’s largest agricultural companies – Bayer, Syngenta and Nufarm. Enko has had great success with its DEL program, providing new molecular starting points in a variety of targets against pests to control weeds, fungi, insects and soil parasites. The company’s approach has won recognition from the World Economic Forum as a technology pioneer for 2021.

About Enko

Enko designs safe and sustainable solutions to the biggest threats to crops today, from pest resistance to new diseases. Applying the latest approaches to the discovery and development of pharmaceuticals from pharmacy to plants, Enko brings an innovative model to agriculture and meets the evolving needs of farmers. Founded in 2017 and led by a team of proven scientists, entrepreneurs and veterans from the agricultural industry, Enko is backed by investors including the Bill and Melinda Gates Foundation, Anterra Capital, Finistere Ventures, Novalis LifeSciences, Germin8 Ventures, TO Ventures Food and Rabo Food & Agri Innovation Fund. Enko is based in Mystic, Connecticut. For more information, visit enkochem.com.

Regarding X-Chem

X-Chem is a leader in small molecule drug discovery services for pharmaceutical and biotechnology companies. As pioneers in DNA-encoded chemical library (DEL) technology, the company is using its market-leading DEL platform to discover new small molecules against challenging, high-value therapeutic targets. As experts in medicinal chemistry, X-Chem can absorb these waters and move them to clinical candidates at an unparalleled rate. During the process, X-Chem’s advanced patented artificial intelligence (AI) technology speeds up all the steps in the process. X-Chem also provides libraries, reagents and information tools that allow DEL operators to get the most out of their DEL platform. X-Chem enables its partners to effectively build drug pipelines from target to clinical candidate, AI-enhanced.

CONTACT:
That close “,” almost
[email protected]

SOURCE Enko

Leave a Comment

Your email address will not be published.